Displaying 29 (all) recruiting clinical trials.
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Nivolumab will be investigated at the Food and Drug Administration (FDA)-approved dose of 480 mg intravenous (IV) every 4 weeks until unacceptable toxicity, disease ...Phase
Interventional
-
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute LeukemiaPhase
Interventional
-
A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors
This is a 2-part, open-label, multicenter, dose escalation and dose expansion study in participants with rapidly accelerated fibrosarcoma, homolog B (BRAF) mutation-positive and/or neuroblastoma ...Phase
Interventional
-
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
The purpose of this study is to test the safety of a study drug called TJ033721. The study will test different dose levels to find ...Phase
Interventional
-
A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
The purpose of this first-in-human (FIH) study is to investigate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), maximum tolerated dose (MTD), recommended Phase 2 dose ...Phase
Interventional
-
A phase 1/1b/2 study evaluating the safety tolerability pharmacokinetics pharmacodynamics and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD ...Phase
Interventional
-
Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)
This is a Phase I, open-label, multicentre trial of BI 1810631 administered orally as a single agent. The trial has two parts; Phase Ia, which ...Phase
Interventional
-
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone or in Combination in Participants with Solid Tumors
This is a 2-part, open-label, Phase 1, multicenter dose-escalation, FIH study of mRNA-4157 monotherapy in subjects with resected solid tumors (Part A) who are in ...Phase
Interventional
-
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810) ADMINISTERED INTRALESIONALLY FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC)
The primary objective is to characterize the safety and tolerability of cemiplimab (also known as REGEN2810) injected intralesionally in patients with recurrent cutaneous squamous cell ...Phase
Interventional
-
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
This is a Phase 1, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in ...Phase
Interventional
